Surgical Treatment and Radioembolization

  • Patricia Martínez-Ortega
  • Fernando Pardo
  • Bruno Sangro
Part of the Medical Radiology book series (MEDRAD)


90Y radioembolization supposes a useful downstaging strategy to reduce tumor burden and increase the proportion of patients eligible for radical treatments in the hepatocellular carcinoma management. Moreover, contralateral hypertrophy is one of the most important advantages of this tactic with compared to other transarterial treatments, and it could be effective not only in hepatocellular carcinoma but also in selected patients with liver metastases. Since these metastases are usually unresectable at initial diagnosis, this treatment has been increasingly used in salvage setting for these patients.


Liver Metastasis Portal Vein Embolization Barcelona Clinic Liver Cancer Milan Criterion Contralateral Hypertrophy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Abdalla EK, Vauthey JN, Ellis LM, Ellis V, Pollock R, Broglio KR, et al (2004) Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 239(6):818, 25 (discussion 825–827)Google Scholar
  2. Ahmadzadehfar H, Biersack HJ, Ezziddin S (2010) Radioembolization of liver tumors with yttrium-90 microspheres. Semin Nucl Med 40(2):105–121PubMedCrossRefGoogle Scholar
  3. Chen WT, Chau GY, Lui WY, Tsay SH, King KL, Loong CC et al (2004) Recurrent hepatocellular carcinoma after hepatic resection: prognostic factors and long-term outcome. Eur J Surg Oncol 30(4):414–420PubMedCrossRefGoogle Scholar
  4. El-Serag HB (2011) Hepatocellular carcinoma. N Engl J Med 365(12):1118–1127PubMedCrossRefGoogle Scholar
  5. Fernandez-Ros N, Silva N, Bilbao JI, Iñarrairaegui M, Benito A, D’Avola D, et al (2013) Partial liver volume radioembolization induces hypertrophy in the spared hemiliver and no major signs of portal hypertension. HPB (Oxford). doi:  10.1111/hpb.12095
  6. Herrero JI, Sangro B, Pardo F, Quiroga J, Iñarrairaegui M, Rotellar F et al (2008) Liver transplantation in patients with hepatocellular carcinoma across Milan criteria. Liver Transpl 14(3):272–278PubMedCrossRefGoogle Scholar
  7. Iñarrairaegui M, Pardo F, Bilbao JI, Rotellar F, Benito A, D’Avola D et al (2012) Response to radioembolization with yttrium-90 resin microspheres may allow surgical treatment with curative intent and prolonged survival in previously unresectable hepatocellular carcinoma. Eur J Surg Oncol 38(7):594–601PubMedCrossRefGoogle Scholar
  8. Khalaf H, Alsuhaibani H, Al-Sugair A, Al-Mana H, Al-Mutawa A, Al-Khadi Y, Al-Sebayel M (2010) Use of Yttrium-90 Microsphere radioembolization of hepatocellular carcinoma as downstaging and bridge before liver transplantation: a case report. Transpl Proc 42:994–998Google Scholar
  9. Kulik LM, Atassi B, van Holsbeeck L, Souman T, Lewandowski RJ, Mulcahy MF et al (2006) Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation. J Surg Oncol 94(7):572–586PubMedCrossRefGoogle Scholar
  10. Lau WY, Lai EC (2007) Salvage surgery following downstaging of unresectable hepatocellular carcinoma-a strategy to increase resectability. Ann Surg Oncol 14(12):3301–3309PubMedCrossRefGoogle Scholar
  11. Lewandowski RJ, Kulik LM, Riaz A, Senthilnathan S, Mulcahy MF, Ryu RK et al (2009) A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant 9(8):1920–1928PubMedCrossRefGoogle Scholar
  12. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX et al (2008) Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100(10):698–711PubMedCrossRefGoogle Scholar
  13. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F et al (1996) Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334(11):693–699PubMedCrossRefGoogle Scholar
  14. Mazzaferro V, Sposito C, Bhoori S, Romito R, Chiesa C, Morosi C et al (2013) Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study. Hepatology 57(5):1826–1837PubMedCrossRefGoogle Scholar
  15. N’Kontchou G, Mahamoudi A, Aout M, Ganne-Carrie N, Grando V, Coderc E et al (2009) Radiofrequency ablation of hepatocellular carcinoma: long-term results and prognostic factors in 235 western patients with cirrhosis. Hepatology 50(5):1475–1483PubMedCrossRefGoogle Scholar
  16. Ravaioli M, Grazi GL, Piscaglia F, Trevisani F, Cescon M, Ercolani G et al (2008) Liver transplantation for hepatocellular carcinoma: results of down-staging in patients initially outside the Milan selection criteria. Am J Transplant 8(12):2547–2557PubMedCrossRefGoogle Scholar
  17. Riaz A, Kulik L, Lewandowski RJ, Ryu RK, Giakoumis Spear G, Mulcahy MF et al (2009) Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres. Hepatology 49(4):1185–1193PubMedCrossRefGoogle Scholar
  18. Rosenbaum CE, Verkooijen HM, Lam MG, Smits ML, Koopman M, van Seeters T et al (2013) Radioembolization for treatment of salvage patients with colorectal cancer liver metastases: a systematic review. J Nucl Med 54:1890–1895Google Scholar
  19. Salem R, Thurston KG (2006) Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. part 1: technical and methodologic considerations. J Vasc Interv Radiol 17(8):1251–1278PubMedCrossRefGoogle Scholar
  20. Tohme S, Sukato D, Chen HW, Amesur N, Zajko AB, Humar A et al (2013) Yttrium-90 radioembolization as a bridge to liver transplantation: a single-institution experience. J Vasc Interv Radiol 24:1632–1638PubMedCrossRefGoogle Scholar
  21. Yao FY, Xiao L, Bass NM, Kerlan R, Ascher NL, Roberts JP (2007) Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am J Transplant 7(11):2587–2596PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Patricia Martínez-Ortega
    • 1
  • Fernando Pardo
    • 1
  • Bruno Sangro
    • 1
  1. 1.Clínica Universidad de NavarraPamplonaSpain

Personalised recommendations